Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT) Revenue
Annual & quarterly revenue history · segment & region breakdown
ARCT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsArcturus Therapeutics Holdings Inc. trailing twelve-month (TTM) revenue is $0.05B, a decrease of 51.43% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | -$0.07B | -51.43% |
| 2024-12-31 | $0.14B | -$0.02B | -12.27% |
| 2023-12-31 | $0.16B | -$0.05B | -23.33% |
| 2022-12-31 | $0.21B | +$0.19B | +1564.82% |
| 2021-12-31 | $0.01B | +$0.00B | +29.56% |
| 2020-12-31 | $0.01B | -$0.01B | -54.12% |
| 2019-12-31 | $0.02B | +$0.01B | +31.97% |
| 2018-12-31 | $0.02B | +$0.00B | +21.20% |
| 2017-12-31 | $0.01B | -$0.01B | -36.23% |
| 2016-12-31 | $0.02B | +$0.01B | +232.06% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Arcturus Therapeutics Holdings Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Arcturus Therapeutics Holdings Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Arcturus Therapeutics Holdings Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ARCT revenue · 4 questionsARCT's trailing twelve-month (TTM) revenue is $0.05B. That is a decrease of 51.43% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Arcturus Therapeutics Holdings Inc. SEC filings · GAAP · Arcturus Therapeutics Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026